Showing results (331-340 of 366) with videos related to
Sort By:
Pageof 37
ACS Chemical Biology|July 2, 2025
Mediator Kinase Inhibitor Selectivity and Activity in Colorectal CancerMaria J Ortiz-Ruiz, Olajumoke Popoola, Konstantinos Mitsopoulos, et al.Oncotarget|September 28, 2013
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug designSylvain Couty, Isaac M Westwood, Andrew Kalusa, et al.Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.Journal of Medicinal Chemistry|January 12, 2026
Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical ProbeJack A O'Hanlon, Katrin Gutsche, Juliane Elisabeth Müller, et al.ACS Medicinal Chemistry Letters|January 8, 2019
Privileged Structures and Polypharmacology within and between Protein FamiliesJoshua Meyers, Nicola E A Chessum, Salyha Ali, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.Cancer Research|June 19, 2007
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinasesFlorence I Raynaud, Suzanne Eccles, Paul A Clarke, et al.Science Translational Medicine|June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinomaNatsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.Pageof 37